CA
NZ
UK
AU
IND
US
…
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -102.01M | -90.27M | -49.56M | -57.20M | -16.15M |
| Net income | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Selling general administrative | 21.45M | 19.41M | 13.16M | 5.29M | 1.48M |
| Reconciled depreciation | 0.07M | 0.08M | 0.06M | 0.02M | 0.01M |
| Ebit | 102.25M | -89.82M | -49.41M | -26.66M | -15.16M |
| Ebitda | -102.25M | -89.74M | -49.35M | -26.64M | -15.16M |
| Depreciation and amortization | -204.50M | 0.08M | 0.06M | 0.02M | 0.01M |
| Non operating income net other | 2.16M | - | -0.20M | - | - |
| Operating income | 102.25M | -89.74M | -49.35M | -26.64M | -15.16M |
| Other operating expenses | 102.25M | 89.74M | 49.35M | 26.64M | 15.16M |
| Interest expense | 1.92M | 0.45M | 0.14M | 30.55M | 0.00M |
| Tax provision | 0.02M | -0.15M | -0.06M | 0.22M | 0.03M |
| Interest income | 2.16M | - | - | - | - |
| Net interest income | 0.24M | - | - | - | - |
| Income tax expense | 0.02M | -0.15M | -0.06M | 0.22M | 0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 102.25M | 89.74M | 49.35M | 26.64M | 15.16M |
| Total other income expense net | -204.26M | -0.53M | -0.20M | -30.56M | -0.99M |
| Net income from continuing ops | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Net income applicable to common shares | -102.03M | -90.12M | -49.50M | -57.42M | -17.65M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 596.27M | 196.82M | 162.42M | 211.07M | 95.55M |
| Other current assets | 14.66M | 7.92M | 11.24M | 5.55M | 1.97M |
| Total liab | 59.96M | 44.99M | 36.47M | 8.11M | 5.61M |
| Total stockholder equity | 536.31M | 151.83M | 125.96M | 202.96M | 89.94M |
| Deferred long term liab | - | - | 0.20M | 0.60M | - |
| Other current liab | 20.53M | 11.94M | 10.19M | 6.05M | 4.62M |
| Common stock | 0.09M | 0.05M | 0.02M | 0.02M | 0.01M |
| Capital stock | 0.09M | 0.05M | 0.02M | 0.02M | 0.01M |
| Retained earnings | -457.43M | -315.24M | -213.22M | -123.09M | -73.60M |
| Other liab | - | 0.50M | 0.03M | - | - |
| Other assets | - | 0.29M | 0.29M | 0.71M | 0.07M |
| Cash | 316.16M | 55.26M | 150.75M | 204.65M | 93.36M |
| Total current liabilities | 29.61M | 24.61M | 19.54M | 8.11M | 5.61M |
| Net debt | -289.05M | -35.21M | -131.35M | -204.65M | -93.36M |
| Short term debt | 0.50M | 0.17M | 2.50M | - | - |
| Short long term debt | - | - | 2.50M | - | - |
| Short long term debt total | 27.11M | 20.05M | 19.40M | - | - |
| Other stockholder equity | 993.46M | 467.37M | 339.22M | 326.05M | 163.53M |
| Property plant equipment | - | 0.09M | 0.15M | 0.17M | 0.15M |
| Total current assets | 593.53M | 196.08M | 161.98M | 210.20M | 95.33M |
| Net tangible assets | - | 151.83M | 125.96M | 202.96M | 89.94M |
| Short term investments | 262.71M | 132.91M | 98.29M | 106.45M | - |
| Long term debt | 24.80M | 19.69M | 16.90M | - | - |
| Accounts payable | 8.59M | 12.50M | 6.84M | 2.06M | 0.99M |
| Accumulated other comprehensive income | 0.19M | -0.35M | -0.06M | -0.01M | -95.55M |
| Common stock total equity | - | 0.05M | - | 0.02M | 0.01M |
| Retained earnings total equity | - | -315.24M | - | -123.09M | - |
| Non currrent assets other | 0.40M | 0.29M | 0.29M | 0.71M | 0.07M |
| Non current assets total | 2.73M | 0.74M | 0.44M | 0.87M | 0.23M |
| Capital lease obligations | 2.31M | 0.35M | - | - | - |
| Long term debt total | - | 19.69M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 118.76M | 7.22M | -106.83M | -0.14M | -0.04M |
| Change to liabilities | 7.41M | 4.78M | 1.13M | -0.52M | 1.65M |
| Total cashflows from investing activities | -33.94M | 7.16M | -106.83M | -0.14M | -0.04M |
| Net borrowings | - | 19.95M | -0.16M | 19.95M | 0.11M |
| Total cash from financing activities | 117.83M | 23.87M | 157.92M | 107.70M | 23.77M |
| Change to operating activities | 4.90M | -1.53M | -2.17M | 1.46M | 1.23M |
| Net income | -102.03M | -90.12M | -49.50M | -57.42M | -16.18M |
| Change in cash | 2.80M | -45.75M | 4.85M | 82.10M | 11.26M |
| Begin period cash flow | 52.46M | 98.21M | 93.36M | 11.26M | 0.00M |
| End period cash flow | 55.26M | 52.46M | 98.21M | 93.36M | 11.26M |
| Total cash from operating activities | -81.09M | -76.78M | -46.24M | -25.46M | -12.47M |
| Issuance of capital stock | 116.69M | 3.29M | 157.68M | 107.70M | 23.66M |
| Depreciation | 0.07M | 0.08M | 0.06M | 0.02M | 0.01M |
| Other cashflows from investing activities | -152.70M | - | - | - | - |
| Sale purchase of stock | 0.05M | 0.14M | 0.13M | 107.70M | 23.66M |
| Other cashflows from financing activities | 1.09M | 20.44M | 0.11M | 20.00M | 23.77M |
| Change to netincome | 10.36M | 9.39M | 4.01M | 31.01M | 1.16M |
| Capital expenditures | 0.01M | 0.06M | 0.13M | 0.14M | 0.04M |
| Cash flows other operating | 4.09M | - | -3.67M | - | - |
| Cash and cash equivalents changes | 2.80M | - | 4.85M | - | - |
| Change in working capital | 10.56M | 3.25M | -1.04M | 0.94M | 2.63M |
| Stock based compensation | 10.36M | 8.68M | 3.81M | 0.39M | 0.11M |
| Other non cash items | -0.04M | 1.48M | 0.50M | 30.60M | 0.98M |
| Free cash flow | -81.10M | -76.84M | -46.37M | -25.60M | -12.51M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
| Name | Title | Year Born |
|---|---|---|
| Ms. Amanda Hill | VP of People & Culture | NA |
| Mr. Rohan Palekar | CEO & Director | 1966 |
| Mr. Quoc Le-Nguyen | Chief Technical Operations Officer & Head of Quality | 1968 |
| Dr. Harry Mansbach M.D. | Chief Medical Officer | 1965 |
| Mr. Ryan Stephen Martins | Chief Financial Officer | 1978 |
| Mr. Shiva K. Natarajan | Sr. VP of Fin. & Principal Accounting Officer | 1966 |
| Ms. Melissa Abel | Sr. VP of Commercial Strategy & Communications | NA |
| Ms. Yun Bai | VP & Head of CMC | NA |
| Mr. Paul Shin | Sr. VP of R&D Operations | NA |
| Mr. Ryan Stephen Martins | Chief Financial Officer | 1979 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...